NewEdge Wealth LLC Raises Stake in Abbott Laboratories $ABT

NewEdge Wealth LLC raised its stake in Abbott Laboratories (NYSE:ABT) by 20.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 59,747 shares of the healthcare product maker’s stock after purchasing an additional 9,944 shares during the quarter. NewEdge Wealth LLC’s holdings in Abbott Laboratories were worth $7,486,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ABT. Invesco Ltd. lifted its position in Abbott Laboratories by 51.0% in the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after purchasing an additional 4,713,135 shares during the last quarter. Ninety One UK Ltd bought a new stake in Abbott Laboratories in the fourth quarter valued at approximately $336,815,000. Vanguard Group Inc. lifted its position in Abbott Laboratories by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after purchasing an additional 2,402,408 shares during the last quarter. Alliancebernstein L.P. lifted its position in Abbott Laboratories by 51.0% in the third quarter. Alliancebernstein L.P. now owns 5,525,906 shares of the healthcare product maker’s stock valued at $740,140,000 after purchasing an additional 1,865,250 shares during the last quarter. Finally, Capital International Investors lifted its position in Abbott Laboratories by 2.5% in the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock valued at $8,251,974,000 after purchasing an additional 1,478,076 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In related news, VP John A. Jr. Mccoy sold 585 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $67,614.30. Following the sale, the vice president directly owned 24,628 shares of the company’s stock, valued at $2,846,504.24. This represents a 2.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the sale, the executive vice president directly owned 146,377 shares in the company, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 3,055 shares of company stock valued at $353,097 over the last 90 days. 0.46% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Oppenheimer lowered their price objective on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. BTIG Research restated a “buy” rating and set a $131.00 target price on shares of Abbott Laboratories in a report on Monday, April 27th. JPMorgan Chase & Co. decreased their target price on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, April 17th. TD Cowen decreased their target price on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a report on Friday, April 17th. Finally, Weiss Ratings downgraded Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $119.43.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Medical Devices segment delivered 8.5% Q1 growth, with electrophysiology, rhythm management, and heart failure products driving gains. That reinforces the company’s long-term growth story and suggests its device portfolio remains a key catalyst for ABT. Abbott’s Medical Device Strategy Supports Long-Term Growth Outlook
• Positive Sentiment: Wall Street analysts remain bullish on Abbott Laboratories despite its recent underperformance versus the broader market, which can help cushion sentiment around the stock. Abbott Laboratories Stock: Analyst Estimates & Ratings
• Positive Sentiment: Wells Fargo reaffirmed its Buy rating on ABT, adding to the view that analysts still see upside potential despite near-term weakness. Wells Fargo Reaffirms Their Buy Rating on Abbott Laboratories (ABT)
• Neutral Sentiment: Erste Group Bank slightly lowered its FY2026 EPS estimate for Abbott to $5.47 from $5.48, which is only a minor change and close to consensus, so the impact looks limited. Abbott Laboratories news item referencing Erste Group Bank estimate reduction
• Negative Sentiment: ABT has underperformed over the past year, and recent share-price weakness has kept investors focused on whether the stock is now cheap rather than on a strong near-term rebound. Is Abbott Laboratories (ABT) Now Offering Value After Recent Share Price Weakness?

Abbott Laboratories Price Performance

Shares of ABT stock opened at $84.24 on Monday. The stock has a market cap of $146.72 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 1.41 and a beta of 0.65. The business’s fifty day moving average is $102.69 and its 200 day moving average is $115.09. Abbott Laboratories has a twelve month low of $84.08 and a twelve month high of $139.06. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.